Norlabdane Compounds Containing Thiosemicarbazone or 1,3-Thiazole Fragments: Synthesis and Antimicrobial Activity

Blaja Svetlana; Lungu Lidia; Kuchkova Kaleria; Ciocarlan Alexandru; Barba Alic; Vornicu Nicoleta; Aricu Aculina

Conţinutul numărului revistei

Articolul precedent

Articolul urmator

757

SM ISO690:2012

BLAJA, Svetlana, LUNGU, Lidia, KUCHKOVA, Kaleria, CIOCARLAN, Alexandru, BARBA, Alic, VORNICU, Nicoleta, ARICU, Aculina. Norlabdane Compounds Containing Thiosemicarbazone or 1,3-Thiazole Fragments: Synthesis and Antimicrobial Activity. In: Chemistry of Natural Compounds, 2021, nr. 1(57), pp. 101-110. ISSN 0009-3130. DOI: https://doi.org/10.1007/s10600-021-03292-3

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

Chemistry of Natural Compounds

Numărul 1(57) / 2021 / ISSN 0009-3130

Norlabdane Compounds Containing Thiosemicarbazone or 1,3-Thiazole Fragments: Synthesis and Antimicrobial Activity

DOI:https://doi.org/10.1007/s10600-021-03292-3

Pag. 101-110

Blaja Svetlana¹, Lungu Lidia¹, Kuchkova Kaleria¹, Ciocarlan Alexandru¹, Barba Alic¹, Vornicu Nicoleta², Aricu Aculina¹

¹ Institute of Chemistry,
² Metropolitan Center of Research TABOR, The Metropolitanate of Moldavia and Bukovina

Disponibil în IBN: 8 aprilie 2021

Rezumat

New di-, tri-, tetra-, and pentanorlabdane compounds with thiosemicarbazone and 1,3-thiazole fragments were synthesized. Their antifungal and antibacterial activities were studied. The main advantages of this research were the available starting material, i.e., the natural labdane diterpenoid (–)-sclareol, which was isolated from renewable resources, and the high probability of biological activity combined with the low toxicity of these compounds because of their natural origin.

Cuvinte-cheie
1, 3-thiazoles, Antimicrobial activity, norlabdane compounds, synthesis, Thiosemicarbazones

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-126852</cfResPublId>
<cfResPublDate>2021-01-28</cfResPublDate>
<cfVol>57</cfVol>
<cfIssue>1</cfIssue>
<cfStartPage>101</cfStartPage>
<cfISSN>0009-3130</cfISSN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/126852</cfURI>
<cfTitle cfLangCode='EN' cfTrans='o'>Norlabdane Compounds Containing Thiosemicarbazone or 1,3-Thiazole Fragments: Synthesis and Antimicrobial Activity</cfTitle>
<cfKeyw cfLangCode='EN' cfTrans='o'>1; 3-thiazoles; Antimicrobial activity; norlabdane compounds; synthesis; Thiosemicarbazones</cfKeyw>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>New di-, tri-, tetra-, and pentanorlabdane compounds with thiosemicarbazone and 1,3-thiazole fragments were synthesized. Their antifungal and antibacterial activities were studied. The main advantages of this research were the available starting material, i.e., the natural labdane diterpenoid (&ndash;)-sclareol, which was isolated from renewable resources, and the high probability of biological activity combined with the low toxicity of these compounds because of their natural origin.&nbsp;</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2021-01-28T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2021-01-28T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-52201</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2021-01-28T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-23821</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2021-01-28T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11165</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2021-01-28T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-12404</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2021-01-28T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11134</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2021-01-28T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-49779</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2021-01-28T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11130</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2021-01-28T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfFedId>
<cfFedIdId>ibn-doi-126852</cfFedIdId>
<cfFedId>10.1007/s10600-021-03292-3</cfFedId>
<cfStartDate>2021-01-28T24:00:00</cfStartDate>
<cfFedId_Class>
<cfClassId>31d222b4-11e0-434b-b5ae-088119c51189</cfClassId>
<cfClassSchemeId>bccb3266-689d-4740-a039-c96594b4d916</cfClassSchemeId>
</cfFedId_Class>
<cfFedId_Srv>
<cfSrvId>5123451</cfSrvId>
<cfClassId>eda2b2e2-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>5a270628-f593-4ff4-a44a-95660c76e182</cfClassSchemeId>
</cfFedId_Srv>
</cfFedId>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-52201</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-52201-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2021-01-28T24:00:00</cfStartDate>
<cfFamilyNames>Blaja</cfFamilyNames>
<cfFirstNames>Svetlana</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-23821</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-23821-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2021-01-28T24:00:00</cfStartDate>
<cfFamilyNames>Lungu</cfFamilyNames>
<cfFirstNames>Lidia</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11165</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11165-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2021-01-28T24:00:00</cfStartDate>
<cfFamilyNames>Kuchkova</cfFamilyNames>
<cfFirstNames>Kaleria</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-12404</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-12404-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2021-01-28T24:00:00</cfStartDate>
<cfFamilyNames>Ciocarlan</cfFamilyNames>
<cfFirstNames>Alexandru</cfFirstNames>
<cfFamilyNames>Чекырлан</cfFamilyNames>
<cfFirstNames>А.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11134</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11134-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2021-01-28T24:00:00</cfStartDate>
<cfFamilyNames>Barba</cfFamilyNames>
<cfFirstNames>Alic</cfFirstNames>
<cfFamilyNames>Барба</cfFamilyNames>
<cfFirstNames>Алик</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-49779</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-49779-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2021-01-28T24:00:00</cfStartDate>
<cfFamilyNames>Vornicu</cfFamilyNames>
<cfFirstNames>Nicoleta</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11130</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11130-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2021-01-28T24:00:00</cfStartDate>
<cfFamilyNames>Aricu</cfFamilyNames>
<cfFirstNames>Aculina</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfSrv>
<cfSrvId>5123451</cfSrvId>
<cfName cfLangCode='en' cfTrans='o'>CrossRef DOI prefix service</cfName>
<cfDescr cfLangCode='en' cfTrans='o'>The service of issuing DOI prefixes to publishers</cfDescr>
<cfKeyw cfLangCode='en' cfTrans='o'>persistent identifier; Digital Object Identifier</cfKeyw>
</cfSrv>
</CERIF>